The priority review is based on results from the phase 3 EV-302 trial.

Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

The oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in over three-fourths of patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer.

The data showed that Black, Hispanic, and uninsured patients were independently associated with a lower likelihood of receiving immunotherapy.

The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).

PSMA-PET is becoming an invaluable tool for the diagnosis and management of oligometastatic prostate cancer patients, a sub-group for whom novel treatment strategies are continuing to emerge.

Concomitant abiraterone or enzalutamide did not boost the radium-223 survival benefit in patients with bone-dominant metastatic castration-resistant prostate cancer.

Surgery following neoadjuvant immune checkpoint inhibition with durvalumab plus tremelimumab was shown to be safe in patients with locally advanced renal cell carcinoma.

No dose-limiting toxicities were observed among the initial 3 patients in cohort 3, and no patients experienced adverse events related to 64Cu-SAR-bisPSMA.

"However, these patients have an overall poor prognosis,” noted Mohamed E. Ahmed, MD.

The investigators observed no dose limiting toxicities or serious adverse events among all patients who received an ARX517 dose of 3.4 mg/kg, the highest dose tested in the trial.

“[18F]DCFPyL was assessed to be a suitable alternative to [68Ga]Ga-PSMA-11 in PCa diagnosis and staging due to its similar lesion uptake rate with no increase in benign uptakes," the authors wrote.

Laura Bukavina, MD, MPH, offers a preview of noteworthy bladder and kidney cancer research to be presented at this year's Society of Urologic Oncology Annual Meeting.

"The findings from this study represent very important reassurance regarding the safety of testosterone as masculinizing treatment," says Joshua Safer, MD, FACP, FACE.

Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.

"This work and previous work supports the idea that EBV not only causes MS, but also continues to affect disease progression," write the authors.

"The conversion factor is slated to undergo a reduction of approximately 3.37% for 2024, decreasing from $33.89 in 2023 to $32.74," write Jonathan Rubenstein, MD, and Mark Painter.

The research projects are assessing combination therapies in advanced prostate cancer that include the use of relugolix.

A recently published study found an association between PARP inhibitor treatment and an increased risk of hematological adverse events, including anemia, thrombocytopenia, and neutropenia, in patients with metastatic castration-resistant prostate cancer.

The phase 2a open-label dose ascending study to assess the safety, tolerability, and efficacy of VMB-100 in female patients with moderate SUI is expected to begin in the first half of 2024.

Technology may save health care professionals’ time and help reduce burnout.

"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.

On an episode of Cleveland Clinic’s Cancer Advances podcast, host Dale Shepard, MD, PhD, talks with Omar Mian, MD, PhD, about emerging molecular biomarkers for genitourinary cancers.

"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.

In a study published in The Lancet Oncology, UC San Francisco researchers conducted a phase 1 clinical trial assessing the combination of 177Lu-PSMA-617 and pembrolizumab in patients with metastatic castration-resistant prostate cancer.